Knowing the Bad: Adverse Event-Informed, High-Risk, Early-Stage Non-Small Cell Lung Cancer Treatment Options

Affiliations

Editorial

Joseph D Phillips. Ann Am Thorac Soc. 2022 Dec.

. 2022 Dec;19(12):1975-1976.

doi: 10.1513/AnnalsATS.202209-756ED.

¹ Section of Thoracic Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.

No abstract available

Figures

Adverse Events Following Limited Resection versus Stereotactic Body Radiation Therapy for Early Stage Lung Cancer.
Wang Q, Stone K, Kern JA, Slatore CG, Swanson S, Blackstock W Jr, Khan RS, Smith CB, Veluswamy RR, Chidel M, Wisnivesky JP. Wang Q, et al. Ann Am Thorac Soc. 2022 Dec;19(12):2053-2061. doi: 10.1513/AnnalsATS.202203-275OC. Ann Am Thorac Soc. 2022. PMID: 35816617 Free PMC article.

1. Cancer Statistics Center, American Cancer Society. Atlanta, GA: American Cancer Society; 2022. https://cancerstatisticscenter.cancer.org/#!/
1. World Health Organization. Geneva: World Health Organization; 2022. https://www.who.int/news-room/fact-sheets/detail/cancer
1. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg . 1995;109:120–129. - PubMed
1. Choi JI. Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes. Transl Lung Cancer Res . 2019;8:32–47. - PMC - PubMed
1. Shin JY, Yoon JK, Marwaha G. Progress in the treatment and outcomes for early-stage non-small cell lung cancer. Lung . 2018;196:351–358. - PubMed